Douglas B. Johnson, MD

Articles

Dr. Johnson on the Rationale for Examining Chronic irAEs Associated With Anti-PD-1 Therapy in Melanoma

May 20th 2021

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

Dr. Johnson on the Risks and Benefits Associated with Anti–PD-1 Therapy in Melanoma

March 31st 2021

Douglas B. Johnson, MD, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.

Dr. Johnson on the Need for Novel Biomarkers in Melanoma

September 15th 2020

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Dr. Johnson on the Limitations of Biomarkers in Melanoma

August 20th 2020

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Dr. Johnson on Applications of Immunotherapy in Melanoma

May 30th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses applications of immunotherapy in melanoma.

Dr. Johnson on Promise of Combination Therapy in Melanoma

April 5th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.